80.71

0.44% -0.36

Pre-market: 80.90 0.19 +0.24%

Kymera Therapeutics Inc (KYMR)

Overview News Price History Option Chain Financials Discussions Forecast

Kymera Therapeutics Inc stock is traded at $80.71, with a volume of 679.80K. It is down -0.44% in the last 24 hours and down -4.97% over the past month. Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Previous Close:

$81.07

Open:

$81.51

24h Volume:

679.80K

Relative Volume:

0.97

Market Cap:

$6.64B

Revenue:

$39.21M

Net Income/Loss:

$-311.35M

P/E Ratio:

-21.94

EPS:

-3.6793

Net Cash Flow:

$-234.34M

1W Performance:

-4.95%

1M Performance:

-4.97%

6M Performance:

+30.51%

1Y Performance:

+133.60%

1-Day Range:

$79.57

$82.54

1-Week Range:

$77.64

$89.03

52-Week Range:

$28.06

$103.00

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name

Kymera Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

857-285-5314

Address

500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN

Employee

238

Twitter

Next Earnings Date

2026-04-30

Latest SEC Filings

KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KYMR Kymera Therapeutics Inc	80.71	6.64B	39.21M	-311.35M	-234.34M	-3.6793
VRTX Vertex Pharmaceuticals Inc	423.92	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	701.42	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	783.50	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	296.11	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	293.86	32.66B	5.36B	287.73M	924.18M	2.5229

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Resumed	Barclays	Overweight
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-03-25	Resumed	Guggenheim	Buy
Oct-24-25	Reiterated	B. Riley Securities	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Sep-18-25	Reiterated	H.C. Wainwright	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-16-25	Initiated	RBC Capital Mkts	Outperform
Jul-30-25	Resumed	B. Riley Securities	Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy
May-20-25	Resumed	Stifel	Buy
Mar-13-25	Initiated	Citigroup	Buy
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Market Perform
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Overweight
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform
Apr-22-24	Initiated	Oppenheimer	Outperform
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-30-23	Initiated	Truist	Buy
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy
Aug-03-22	Initiated	Goldman	Buy
Jul-20-22	Initiated	SVB Leerink	Mkt Perform
Apr-28-22	Initiated	Credit Suisse	Outperform
Mar-10-22	Initiated	JP Morgan	Neutral
Feb-10-22	Initiated	Wells Fargo	Overweight
Sep-30-21	Initiated	B. Riley Securities	Neutral
Sep-30-21	Initiated	Stifel	Buy
Sep-10-21	Downgrade	BofA Securities	Buy → Neutral
May-21-21	Initiated	UBS	Buy
Apr-14-21	Initiated	Berenberg	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Sep-15-20	Initiated	BofA Securities	Neutral
Sep-15-20	Initiated	Cowen	Outperform
Sep-15-20	Initiated	Guggenheim	Buy
Sep-15-20	Initiated	Morgan Stanley	Equal-Weight

View All

Kymera Therapeutics Inc Stock (KYMR) Latest News

May 03, 2026

Understanding Momentum Shifts in (KYMR) - Stock Traders Daily

May 03, 2026

Kymera Therapeutics Q1 2026 earnings preview - MSN

May 03, 2026

May 02, 2026

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR) and Teleflex (TFX) - The Globe and Mail

May 02, 2026

Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN

May 02, 2026

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR) - The Globe and Mail

May 02, 2026

Jennison Associates LLC Decreases Stock Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

May 02, 2026

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen - MarketBeat

May 02, 2026

May 01, 2026

Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $119 - Moomoo

May 01, 2026

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration - Yahoo Finance

May 01, 2026

HC Wainwright & Co. Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN

May 01, 2026